Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JR11-TCO
- Development stage
- Preclinical
- Lead developer
- Erasmus MC
- Modality
- Peptides
- Administration
- Intravenous
01
Overview
JR11-TCO is a somatostatin receptor subtype 2 (SSTR2) antagonist peptide (JR11) covalently modified with a trans-cyclooctene (TCO) group and a DOTA chelator. It is developed for use in a pretargeted radionuclide therapy strategy for neuroendocrine tumors (NETs). In this approach, JR11-TCO is administered first to target and bind SSTR2-expressing tumor cells. Subsequently, a radiolabeled tetrazine (Tz) molecule (such as [111In]In-tetrazine) is administered, which rapidly and selectively conjugates with the prelocalized JR11-TCO via an in vivo bioorthogonal inverse electron-demand Diels-Alder (IEDDA) click chemistry reaction. This pretargeting strategy aims to deliver high doses of therapeutic radiation to the tumor while minimizing systemic exposure and healthy organ accumulation.
- Other names
- TCO-JR11TCO-JR-11TCO-JR 11TCO-modified JR11
02
Targets
SSTR2 (Somatostatin receptor type 2)
Beyond the preview
Go deeper on JR11-TCO.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JR11-TCO.